Ex-FDA neu­ro chief Bil­ly Dunn is tak­ing a spin through the re­volv­ing door with bio­phar­ma — and that's a prob­lem

It’s been less than three months since the FDA put out word that Bil­ly Dunn had left the agency fol­low­ing a con­tro­ver­sial run high­light­ed by a calami­tous de­ci­sion to ap­prove Bio­gen’s Alzheimer’s drug, Aduhelm. And he didn’t leave much room for a break.

On Tues­day night we learned, via press re­lease, that Prothena CEO Gene Kin­ney had signed him up for a lu­cra­tive board post, where no doubt Dunn can play a help­ful role in guid­ing them through the FDA process as they ad­vance their own neu­ro drugs through the clin­ic.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.